

[Menu](#)**Cleveland Clinic****Center for Continuing Education**

2016 Pulmonary Hypertension Summit Webcast Series

Pulmonary Arterial Hypertension in COPD and ILD

Release Date: June 29, 2016**Expiration Date:** June 29, 2018**Estimated Time of Completion:** 1 hour

Description

[2016 Pulmonary Hypertension Summit Webcast Series](#) reviews pulmonary hypertension diagnosis and treatment, including the most recent advances in the context of challenges faced by physicians and other health care providers caring for these patients.

This webcast reviews Pulmonary Arterial Hypertension in chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD), including diagnosis, treatment strategies and targeted therapy outcomes.

Learning Objectives

1. Develop knowledge of the association between interstitial lung disease (ILD) and pulmonary hypertension (PH).
2. Identify important clinical clues to the presence of PH in ILD.
3. Review the promise and pitfalls of treating PH associated with ILD.

Target Audience

These activities are directed to physicians, physician assistants, and nurses with an interest in

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation

Activity Directors and Faculty

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias. The following faculty have indicated that they may have a relationship which, in the context of their contribution, could be perceived as a potential conflict of interest:

Raed A. Dweik, MD

Bayer Healthcare

Consulting, scientific advisory capacity

Gustavo A. Heresi, MD

Bayer Healthcare

Membership on advisory; committee or review panels; Teaching and Speaking

United Therapeutics Corporation

Membership on advisory committee or review panels

Steven D. Nathan, MD

Bayer Healthcare; Gilead Sciences, Inc.

Consulting; Membership on advisory committee or review panels

United Therapeutics Corporation

Consulting

Boehringer Ingelheim

Consulting Membership on advisory committee or review panels; Teaching and Speaking

Genentech/Roche

Consulting; Teaching and Speaking

Franck Rahaghi, MD

Actelion; Bayer Healthcare; Gilead Sciences, Inc.; Consulting; Teaching and Speaking
Lung Rx; United Therapeutics Corporation

The following faculty has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest:

Samar Farha, MD

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this activity from:

Actelion Pharmaceuticals US, Inc.
Bayer HealthCare Pharmaceuticals
Gilead Sciences, Inc.

United Therapeutics Corporation and Lung Biotechnologies

Begin Activity

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education and the [Cleveland Clinic Respiratory Institute](#).